

Fact sheet reference list

- American Academy of Pediatrics. Pertussis (whooping cough). In: Pickering L, Baker C, Kimberlin D, Long S, editors. Red book: 2009 report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 504-18.
- Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): A review of evidences and recommendations. *Vaccine*. 2012;30(35):5179-90.
- Bonhoeffer J, Heininger U. Adverse events following immunization: Perception and evidence. *Curr Opin Infect Dis*. 2007;20(3):237-46.
- Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS, the VAERS Working Group. Infant immunization with acellular pertussis vaccines in the United States: Assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). *Pediatrics*. 2000;106(4):e51.
- Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, et al. Hypotonic-hypo-responsive episode (HHE) as an adverse event following immunization in early childhood: Case definition and guidelines for data collection, analysis, and presentation. *Vaccine*. 2007;25(31):5875-81.
- Centers for Disease Control and Prevention. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2011;60(RR-02):1-61.
- Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older – Advisory Committee on Immunization Practices (ACIP), 2012. *MMWR Morb Mortal Wkly Rep*. 2012;61(25):468-70.
- Centers for Disease Control and Prevention. Pertussis (whooping cough): Clinical complications [Home page on the Internet]. Atlanta: Centers for Disease Control and Prevention; 2012 [updated 2010 August 26; cited 2013 January 15]. Available from: <http://www.cdc.gov/pertussis/clinical/complications.html>.
- Centers for Disease Control and Prevention. Pertussis (whooping cough): Complications [Home page on the Internet]. Atlanta: Centers for Disease Control and Prevention; 2012 [updated 2012 June 20; cited 2013 January 15]. Available from: <http://www.cdc.gov/pertussis/about/complications.html>.
- Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women – Advisory Committee of Immunization Practices (ACIP), 2012. *MMWR Morb Mortal Wkly Rep*. 2013;62(7):131-5.
- Cherry JD. Epidemic pertussis in 2012: The resurgence of a vaccine-preventable disease. *N Engl J Med*. 2012;367(9):785-7.
- Clark TA, Messonnier NE, Hadler SC. Pertussis control: Time for something new? *Trends Microbiol*. 2012;20(5):211-3.
- Committee on Infectious Diseases, American Academy of Pediatrics. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). *Pediatrics*. 2011;128(4):809-12.
- Crowcroft NS, Pebody RG. Recent developments in pertussis. *Lancet*. 2006;367(9526):1926-36.
- Edwards KM. Overview of pertussis: Focus on epidemiology, sources of infection, and long term protection after infant vaccination. *Pediatr Infect Dis J*. 2005;24(6):S104-8.
- Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin S, Orenstein W, Offit P, editors. *Vaccines*. 6th ed. London: W.B. Saunders; 2013. p. 447-92.
- Elliott E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. *Pediatr Infect Dis J*. 2004;23(3):246-52.
- Godfroid F, Denoel P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? *Expert Rev Vaccines*. 2005;4(5):757-78.
- Goodwin H, Nash M, Gold M, Heath TC, Burgess MA. Vaccination of children following a previous hypotonic-hypo-responsive episode. *J Paediatr Child Health*. 1999;35(6):549-52.
- Grant CC, Roberts M, Scragg R, Stewart J, Lennon D, Kivell D, et al. Delayed immunisation and risk of pertussis in infants: Unmatched case-control study. *BMJ*. 2003;326(7394):852-3.
- Halperin S, De Serres G. Pertussis. In: Evans A, Brachman P, editors. *Bacterial infections of humans: Epidemiology and control*. New York: Springer; 2009. p. 577-96.
- Heininger U. Pertussis immunisation in adolescents and adults. In: Finn A, Pollard A, editors. *Hot topics in infection and immunity in children IV*. New York: Springer; 2008. p. 72-97.
- Immunisation Action Coalition. Is there guidance for pertussis protection for an adult who cannot receive the tetanus portion of the Tdap vaccine because of allergy? *Needle Tips*. 2012;22(3):5.
- Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. *Vaccine*. 2003;21(17-18):2003-14.
- Juretzko P, von Kries R, Hermann M, von König CHW, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. *Clin Infect Dis*. 2002;35(2):162-7.
- Kerr JR, Matthews RC. Bordetella pertussis infection: Pathogenesis, diagnosis, management, and the role of protective immunity. *Eur J Clin Microbiol Infect Dis*. 2000;19(2):77-88.
- Knuf M, Zepp F, Meyer C, Grzegowski E, Wolter J, Riffelmann M, et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. *Vaccine*. 2006;24(12):2043-8.
- Medsafe. Datasheet: ADT Booster [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2010 [cited 2012 December 7]. Available from: <http://www.medsafe.govt.nz/profs/Datasheet/a/ADTBoosterinj.pdf>.
- Medsafe. Datasheet: Boostrix [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2011 [cited 2012 December 7]. Available from: <http://www.medsafe.govt.nz/profs/Datasheet/b/Boostrixinj.pdf>.
- Ministry of Health. Immunisation handbook 2011. Wellington: Ministry of Health; 2011.
- Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. *Lancet Infect Dis*. 2007;7(9):614-24.
- Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, van Rie A, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. *Vaccine*. 2003;21(17-18):2015-21.
- Ray P, Hayward J, Michelson D, Lewis E, Schwalbe J, Black S, et al. Encephalopathy after whole-cell pertussis or measles vaccination: Lack of evidence for a causal association in a retrospective case-control study. *Pediatr Infect Dis J*. 2006;25(9). Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. *Semin Pediatr Infect Dis*. 2003;14(3):196-8.
- Scheifele DW, Ochnio JJ, Halperin S. Cellular Immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. *Pediatr Infect Dis J*. 2009;28(11):985-9.
- van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. *Pediatr Infect Dis J*. 2005;24(5):S62-5.
- Wendelboe AM, Van Rie A, Salmasso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. *Pediatr Infect Dis J*. 2005;24(5):S58-61.
- Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, et al. Rationale for pertussis booster vaccination throughout life in Europe. *Lancet Infect Dis*. 2011;11(7):557-70.